Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 2/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.63 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30467929 | 1.00 | PDGFRA (0.69) | PDGFRAPDGFRBKDRFGFR2EGFR | |
| SCHEMBL22505699 | 0.94 | PDGFRA (0.60) | PDGFRAPDGFRBKDRFGFR2EGFR | |
| SCHEMBL15960723 | 0.91 | PDGFRA (0.57) | PDGFRAPDGFRBKDRFGFR2EGFR | |
| SCHEMBL14139300 | 0.91 | PDGFRA (0.58) | PDGFRAPDGFRBKDRFGFR2EGFR | |
| SCHEMBL4365396 | 0.89 | PDGFRB (0.76) | PDGFRAPDGFRBKDRFGFR2EGFR | |
| SCHEMBL5208322 | 0.88 | PDGFRB (0.55) | PDGFRAPDGFRBKDRFGFR2EGFR | |
| SCHEMBL168048 | 0.88 | PDGFRB (0.79) | PDGFRAPDGFRBKDRFGFR2EGFR | |
| SCHEMBL19957409 | 0.87 | PDGFRB (0.53) | PDGFRAPDGFRBKDRFGFR2EGFR | |
| SCHEMBL28125152 | 0.87 | PDGFRA (0.53) | PDGFRAPDGFRBKDRFGFR2EGFR | |
| SCHEMBL19957069 | 0.87 | PDGFRA (0.53) | PDGFRAPDGFRBKDRFGFR2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4654968-A1 | PROCESS FOR THE PREPARATION OF TIVOZANIB OR A SALT THEREOF | Alivus Life Sciences Limited (IN) | 2025-12-03 | — | — | EP | claimed |
| WO-2024157170-A1 | PROCESS FOR THE PREPARATION OF TIVOZANIB OR A SALT THEREOF | GLENMARK LIFE SCIENCES LIMITED (IN) | 2024-08-02 | — | — | WO | claimed |
| US-20260049059-A1 | A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB | SYNTHON BV (NL) | 2026-02-19 | — | — | US | disclosed |
| EP-4654968-A1 | PROCESS FOR THE PREPARATION OF TIVOZANIB OR A SALT THEREOF | Alivus Life Sciences Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| EP-4622961-A1 | A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB | Synthon B.V. (NL) | 2025-10-01 | — | — | EP | disclosed |
| WO-2024157170-A1 | PROCESS FOR THE PREPARATION OF TIVOZANIB OR A SALT THEREOF | GLENMARK LIFE SCIENCES LIMITED (IN) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024110606-A1 | A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB | SYNTHON B.V. (NL) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024110606-A1 | A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB | SYNTHON B.V. (NL) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024095127-A1 | SOLID STATE FORMS OF TIVOZANIB AND PROCESS FOR PREPARATION THEREOF | PLIVA HRVATSKA D.O.O. (HR) | 2024-05-10 | — | — | WO | disclosed |
| CN-116478090-A | Preparation method of tivozanib key intermediate | 上海天慈生物谷生物工程有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-116478090-A | Preparation method of tivozanib key intermediate | 上海天慈生物谷生物工程有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20040209905-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-10-21 | — | — | US | disclosed |
| US-6797823-B1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1384712-A1 | Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-1382604-A1 | QUINOLINE DERIVATIVE HAVING AZOLYL GROUP AND QUINAZOLINE DERIVATIVE | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-01-21 | — | — | EP | disclosed |
| EP-1153920-B1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES | KIRIN BREWERY (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-20030087907-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (JP) | 2003-05-08 | — | — | US | disclosed |
| EP-1243582-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-1153920-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES | KIRIN BEER KABUSHIKI KAISHA (JP) | 2001-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049059-A1 | A PROCESS FOR PREPARATION OF CABOZANTINIB OR TIVOZANIB | KRAS, PDGFRB, BRAF | PDGFRA 4/4885PDGFRB 2/4885KDR 79/4885 |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | PDGFRA 1/4885PDGFRB 2/4885KDR 5/4885 |
| US-20040209905-A1 | Quinoline derivatives and quinazoline derivatives | RABL3, NRAS, CYTH3 | PDGFRA 3103/4885PDGFRB 3503/4885KDR 3106/4885 |
| US-20030087907-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | NQO2, H1-5, NRAS | PDGFRA 4104/4885PDGFRB 4361/4885KDR 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.